期刊文献+

慢性HBV感染患者抗原特异性CTL的肝损伤作用 被引量:3

下载PDF
导出
摘要 目的探讨抗原表位特异性CTL在慢性乙型肝炎发病中的作用。方法用4个HBV抗原表位肽四聚体对外周血中抗原特异性CTL进行检测[HBV抗原表位肽分别为HBcAg18-27,序列为FLPSDFFPSV(C18),HBsAg183~191,序列为WLSLLVPFV(E183),HBeAg335-343,序列FLLTRILTI(E335),多聚酶P的575~583序列为FLLSLGIHL(P1575)],检测慢性乙型肝炎患者肝炎发作时病毒抗原表位特异性CTL出现频率,分析抗原表位特异性CTL频率与血清ALT水平的相关关系,分析各组间抗原表位特异性CTL频率的差异。结果36例慢性HBV感染患者抗原表位特异性CTL检测阳性33例(92%),HBeAg183~191表位特异性CTL频率高于其他3个(P〈0.05)。统计分析抗原表位特异性CTL频率血清ALT水平相关性不显著;分组对比发现血清ALT升高5-10倍组多个抗原表位特异性CTL水平高于其他组(P〈0.05)。结论慢性HBV感染患者外周血中存在抗原表位特异性CTL,但特异性CTL的存在并不能代表保护性免疫。认为抗原表位特异性CTL在肝炎发作过程中具有肝组织损害作用,肝损伤作用可能比较轻微。
出处 《广东医学》 CAS CSCD 北大核心 2006年第5期671-673,共3页 Guangdong Medical Journal
基金 国家自然科学基金资助项目(编号:30200242)
  • 相关文献

参考文献12

  • 1PERRILLO R P, LAI C L, LIAW Y F, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B [J]. Hepatology,2002, 36: 186.
  • 2GUIDOTTI L G, CHISARI F V. Noncytolytic control of viral infections by the innate and adaptive immune response[J]. Annu Rev Immunol,2001, 19: 65.
  • 3GUIDOTTI L G. The role af cytoto:dc T cells and cytokines in the control af hepatitis B virus infection[J]. Vaccine, 2002, 20(Suppl 4):A80.
  • 4TSAI S L, LEE T H, CHIEN R N, et al. A method to increase tetrainer staining efficiency af CD8^+ T cells with MHC - peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment[J]. J Immunol Methods, 2004,285: 71.
  • 5CHEN G, SHANKAR P, LANGE C, et al. CD8 T cells specific for human immunodeficiency vires, Epstein - Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection[J]. Blood, 2001, 98: 156.
  • 6KAKIMI K, ISOGAWA M, CHUNG J, et al. Immunogenicity and tolerogenicity af hepatitis B virus swactural and nonstractural proteins:implications for immunotherapy af persistent viral infections[J]. J Virol, 2002, 76: 8609.
  • 7FERRARI C, MISSALE G, BONI C, et al. Immunopathogenesis of hepatitis B[J]. J Hepatol, 2003, 39(Suppl 1):S36.
  • 8REIGNAT S, WEBSTER G J, BROWN D, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection[J]. J Exp Med, 2002, 195: 1089.
  • 9王洪,王宇明.慢性乙型肝炎肝炎发作的临床意义[J].解放军医学杂志,2004,29(10):920-922. 被引量:1
  • 10TSUBOTA A, ARASE Y, SUZUKI F, et al. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mtants in long- term lamivudine therapy for hepatitis B e antigen - positive chronic hepatitis B[J]. J Med Virol, 2004, 73: 7.

二级参考文献21

  • 1[1]Sablon E, Shapiro F, Zoulim F et al . Early detection of hepatitis B drug resistance: implications for patient management. Expert Rev Mol Diagn, 2003,3(5):535
  • 2[2]Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology, 2001,120(4):1009
  • 3[3]Hsu YS, Chien RN, Yeh CT et al . Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology, 2002,35(6):1522
  • 4[4]Shimada N, Yamamoto K, Kuroda MJ et al . HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells. J Clin Immunol, 2003,23(3):223
  • 5[5]Akuta N, Tsubota A, Suzuki F et al . Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis-an open-cohort study. J Hepatol, 2003,38(1):91
  • 6[6]Tsubota A, Arase Y, Suzuki F et al . Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. J Med Virol, 2004,73(1):7
  • 7[7]Chien RN, Liaw YF. Short-term lamivudine therapy in patients with chronic hepatitis B. Intervirology, 2003,46(6):362
  • 8[8]Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol, 1998,13(1):14
  • 9[9]Tsai SL, Sheen IS, Chien RN et al . Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci, 2003,10(1):120
  • 10[10]Perrillo RP, Lai CL, Liaw YF et al . Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. 2002,36(1):186

同被引文献13

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部